Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Aplenc

Showing results (181-190 of 254) with videos related to

Pageof 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2017
CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531Jatinder K Lamba, Lata Chauhan, Miyoung Shin, et al.
International Journal of Cancer|October 31, 2015
Impact of registration on clinical trials on infection risk in pediatric acute myeloid leukemiaDavid Dix, Richard Aplenc, Lynette Bowes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2019
Functional Properties of <i>KIT</i> Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid LeukemiaKatherine Tarlock, Todd A Alonzo, Yi-Cheng Wang, et al.
Frontiers in Cardiovascular Medicine|July 1, 2024
Cardiotoxicity of CPX-351 in children and adolescents with relapsed AML: a Children's Oncology Group reportKasey J Leger, Michael J Absalon, Biniyam G Demissei, et al.
Cancer|November 20, 2023
Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemiaJenny Ruiz, Yimei Li, Lusha Cao, et al.
Leukemia & Lymphoma|January 5, 2016
A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology GroupTamara P Miller, Kelly D Getz, Marko Kavcic, et al.
Blood Advances|October 20, 2020
Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 reportLisa Eidenschink Brodersen, Robert B Gerbing, M Laura Pardo, et al.
Pediatric Blood & Cancer|October 1, 2021
Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology GroupCaitlin W Elgarten, Andrew C Wood, Yimei Li, et al.
Blood Advances|January 31, 2024
Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemiaKatherine Tarlock, Robert B Gerbing, Rhonda E Ries, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2022
Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3</i>/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031Jessica A Pollard, Todd A Alonzo, Robert Gerbing, et al.
Pageof 26

Showing results (181-190 of 254) with videos related to

Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2017
CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531Jatinder K Lamba, Lata Chauhan, Miyoung Shin, et al.
International Journal of Cancer|October 31, 2015
Impact of registration on clinical trials on infection risk in pediatric acute myeloid leukemiaDavid Dix, Richard Aplenc, Lynette Bowes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2019
Functional Properties of <i>KIT</i> Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid LeukemiaKatherine Tarlock, Todd A Alonzo, Yi-Cheng Wang, et al.
Frontiers in Cardiovascular Medicine|July 1, 2024
Cardiotoxicity of CPX-351 in children and adolescents with relapsed AML: a Children's Oncology Group reportKasey J Leger, Michael J Absalon, Biniyam G Demissei, et al.
Cancer|November 20, 2023
Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemiaJenny Ruiz, Yimei Li, Lusha Cao, et al.
Leukemia & Lymphoma|January 5, 2016
A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology GroupTamara P Miller, Kelly D Getz, Marko Kavcic, et al.
Blood Advances|October 20, 2020
Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 reportLisa Eidenschink Brodersen, Robert B Gerbing, M Laura Pardo, et al.
Pediatric Blood & Cancer|October 1, 2021
Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology GroupCaitlin W Elgarten, Andrew C Wood, Yimei Li, et al.
Blood Advances|January 31, 2024
Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemiaKatherine Tarlock, Robert B Gerbing, Rhonda E Ries, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2022
Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3</i>/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031Jessica A Pollard, Todd A Alonzo, Robert Gerbing, et al.
Pageof 26